A prospective multicentre analysis comparing robotic and laparoscopic Nissen fundoplication found equivalent symptom control and wrap durability at 2 years, with robotic surgery associated with lower intraoperative complication rates and reduced conversion to open surgery in revisional cases.
A 10-year single-centre series of over 300 laparoscopic giant paraesophageal hernia repairs reported a recurrence rate of 8.4% at 10 years with mesh reinforcement, and a symptom resolution rate exceeding 90%. Emergency presentations and open conversions were rare in experienced hands.
Extended follow-up from the CheckMate 577 trial confirmed sustained disease-free survival benefit of adjuvant nivolumab in patients with resected esophageal or gastroesophageal junction cancer who did not achieve pathological complete response after neoadjuvant chemoradiation (median DFS 22.4 vs. 11.0 months, HR 0.67).
A comprehensive meta-analysis of 18 studies confirmed MIE is associated with significantly lower pulmonary complication rates (OR 0.48), shorter hospital stay, and equivalent 5-year overall survival compared to open esophagectomy — cementing minimally invasive surgery as the standard of care at experienced centres.
Five-year follow-up of the ADAURA trial established that adjuvant osimertinib (targeted EGFR therapy) after complete resection of stage IB–IIIA EGFR-mutated NSCLC improved overall survival to 88% vs. 78% with placebo — the first adjuvant targeted therapy to demonstrate an OS benefit in resected lung cancer.
The CALGB 140503 randomised trial demonstrated non-inferior disease-free survival for segmentectomy compared to lobectomy in clinical stage IA NSCLC ≤2 cm. Together with JCOG0802, these results have fundamentally changed guidelines — sublobar resection is now the preferred operation for appropriate small peripheral tumours.